345 related articles for article (PubMed ID: 25778705)
1. Tumor profiling of gastric and esophageal carcinoma reveal different treatment options.
Miura JT; Xiu J; Thomas J; George B; Carron BR; Tsai S; Johnston FM; Turaga KK; Gamblin TC
Cancer Biol Ther; 2015; 16(5):764-9. PubMed ID: 25778705
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S
Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611
[TBL] [Abstract][Full Text] [Related]
3. Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.
Borazanci E; Millis SZ; Kimbrough J; Doll N; Von Hoff D; Ramanathan RK
J Gastrointest Oncol; 2017 Feb; 8(1):164-172. PubMed ID: 28280620
[TBL] [Abstract][Full Text] [Related]
4. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract][Full Text] [Related]
5. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
6. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.
Koopman T; Smits MM; Louwen M; Hage M; Boot H; Imholz AL
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1343-51. PubMed ID: 25544671
[TBL] [Abstract][Full Text] [Related]
7. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
[TBL] [Abstract][Full Text] [Related]
8. Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy.
Potkonjak M; Miura JT; Turaga KK; Johnston FM; Tsai S; Christians KK; Gamblin TC
HPB (Oxford); 2015 Dec; 17(12):1119-23. PubMed ID: 26374242
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
10. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
Hashimoto T; Nakamura Y; Mishima S; Nakayama I; Kotani D; Kawazoe A; Kuboki Y; Bando H; Kojima T; Iida N; Shibuki T; Imai M; Fujisawa T; Nagamine M; Sakamoto N; Kuwata T; Yoshino T; Shitara K
Cancer Sci; 2024 May; 115(5):1622-1633. PubMed ID: 38429886
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling in gastric cancer: examining potential targets for chemotherapy.
Miura JT; Johnston FM; Thomas J; George B; Eastwood D; Tsai S; Christians KK; Turaga KK; Gamblin TC
J Surg Oncol; 2014 Sep; 110(3):302-6. PubMed ID: 24844210
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
14. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
15. Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.
Gleeson EM; Feldman R; Mapow BL; Mackovick LT; Ward KM; Morano WF; Rubin RR; Bowne WB
Am J Clin Oncol; 2018 Aug; 41(8):777-783. PubMed ID: 28263231
[TBL] [Abstract][Full Text] [Related]
16. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
17. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
Cappellesso R; Fassan M; Hanspeter E; Bornschein J; d'Amore ES; Cuorvo LV; Mazzoleni G; Barbareschi M; Pizzi M; Guzzardo V; Malfertheiner P; Micev M; Guido M; Giacomelli L; Tsukanov VV; Zagonel V; Nitti D; Rugge M
Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
[TBL] [Abstract][Full Text] [Related]
19.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
20. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.
Personeni N; Baretti M; Bozzarelli S; Spaggiari P; Rubino L; Tronconi MC; Fumagalli Romario U; Rosati R; Giordano L; Roncalli M; Santoro A; Rimassa L
Gastric Cancer; 2017 May; 20(3):428-437. PubMed ID: 27530622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]